Does My Lead Investor Need My Consent to Sell to Their Own Continuation Fund?

Your lead investor just sent you a consent request.

They want to sell their stake in your company to a new investment vehicle.

That sounds routine until you look at who controls the buyer.

It is the same investment manager.

The fund currently holding your shares wants to sell them to a continuation fund that the same GP controls. You have been given a deadline and asked to sign.

Before you do, there is an important question:

Do you actually have to consent to the transfer?

Continuation funds have become an increasingly common tool in the private markets. They can provide liquidity to existing investors while allowing a GP to continue holding an attractive portfolio company. But when the same manager effectively sits on both sides of the transaction, the deal creates a clear conflict of interest. Founders should understand their rights before approving a transfer that could change the company’s ownership, governance, and future fundraising dynamics.

What Is a Continuation Fund?

A continuation fund allows a general partner (GP) to move a portfolio company from an existing fund into a new investment vehicle that the same GP or manager also controls. Instead of selling the company stake to an unrelated outside buyer, the investment moves to the new fund.

The structure has become increasingly important in the secondary market.

Secondary market transaction volume exceeded $120 billion during the first half of 2026, representing approximately 20% year-over-year growth. GP-led single-asset transactions accounted for more than half of that activity.

That means founders and companies are increasingly likely to encounter these transactions as venture and private-market investors look for ways to extend their ownership periods.

Why Is There a Conflict of Interest?

A continuation fund transaction is different from a straightforward sale to an unrelated investor.

The same GP may influence both sides of the transaction.

GP can have influence over the price, timing, and economics of the transaction while potentially earning carried interest on both sides.

That creates an obvious question:

Who is negotiating for the company’s interests?

The seller and buyer may ultimately report to the same management team.

That does not automatically make the transaction improper.

It does mean the transaction deserves closer scrutiny than an ordinary transfer between unrelated investors.

Do You Actually Have a Right to Block the Transfer?

There is no universal answer.

Your rights depend on the company’s existing governing documents.

Charter and stockholders’ agreement are documents that may determine whether the company, board, or founders have consent rights over the transfer.

Potential restrictions may include:

• Board or company approval requirements.
• Right of First Refusal (ROFR) provisions.
• Other transfer restrictions that apply to particular investors or transactions.

Do not assume you have no leverage simply because the investors describe the transaction as an internal fund transfer.

Your rights are determined by the documents, not by the label placed on the transaction.

The Sale Can Change Your Governance

A continuation fund does more than change the name appearing on your cap table.

The new vehicle may have different governance rights, different investment timelines, and different expectations for the company’s next financing or exit.

There are several potential changes, including:

• New board representatives with different priorities.
• A longer expected timeline for liquidity.
• New governance terms that may affect negotiating leverage in a future financing.

For founders, these changes can matter even if the company’s day-to-day operations remain exactly the same.

Your next board meeting could involve a new representative.

Your next financing could involve a different set of expectations.

And an exit that previously appeared to be approaching may now be expected to happen much later.

Independent Review of the Price Matters

One of the most important questions is whether the transfer price fairly reflects the value of the company’s shares.

The GP is potentially conflicted because the same manager is involved with both the selling fund and the purchasing continuation vehicle.

It is recommended to have an independent counsel review of the sale valuation rather than simply accepting the price provided by the GP.

Founders do not necessarily need to determine the value themselves.

They do need to understand whether the process used to establish that value was independent enough to give them confidence in the transaction.

Ask What Happens to the New Fund Economics

The continuation fund may have a different economic structure from the original fund.

Ask about the carry and fee arrangements that apply to the new vehicle.

This matters because the economics of the new fund can influence the GP’s incentives and the way it approaches future decisions involving the portfolio company.

Before signing a consent request, founders should understand the new fund’s basic structure and how it differs from the existing investor relationship.

Do Not Let the Deadline Rush You

Consent requests often arrive with a specific signature deadline.

That can create unnecessary pressure.

But if the transaction affects your transfer rights, governance, board representation, or cap table, it is reasonable to understand what you are approving before signing.

Confirm that you have enough time to review the transaction before the deadline.

A short deadline should not substitute for understanding your legal rights.

Common Founder Mistakes

• Skipping independent review of the sale price: The GP may have interests on both sides of the transaction, making independent review particularly important.
• Assuming you have no consent or blocking rights: Transfer restrictions, ROFR provisions, and board approval requirements may give the company or founders meaningful rights that are easy to overlook.
• Treating the transaction as investor housekeeping: A new fund can bring different board representatives, economic terms, governance rights, and expectations around the company’s future.
• Signing simply because there is a deadline: Founders should understand what they are consenting to and whether the requested approval is actually required under the company’s governing documents.

10-Minute Continuation Fund Self Check

• Does the company’s charter require approval for this transfer?
• Does the stockholders’ agreement contain any transfer restrictions or ROFR provisions?
• Has independent counsel reviewed the proposed valuation?
• Do I know who will represent the continuation fund on the board?
• Have I asked what fees and carried interest apply to the new vehicle?
• Do I understand how the transaction changes my cap table and governance?
• Have I been given enough time to review the consent request?

If you cannot answer yes to all of these, do not sign the consent request yet.

Bottom Line

A continuation fund transaction can be a legitimate way for an investor to provide liquidity while continuing to support a strong portfolio company. But when the same GP controls both the selling fund and the new buyer, founders should not treat the transaction as routine paperwork.

The key questions are straightforward: What rights do your governing documents give you? How was the transaction priced? Who will control the investment after the transfer? And how will the new fund change your governance and future financing dynamics?

Check those answers before signing the consent.

Getting a Consent Request Tied to a Continuation Fund Sale?

Our launch-ready legal package is tailored to your business, your existing agreements, and the transaction you’re considering. Schedule a free 30-minute discovery call to discuss your situation, understand your rights, and determine whether our team can help you navigate the proposed transfer.

Book here: Initial Consultation with Primum Law Group